Update information

Update information

October 2019: A footnote has been added to recommendations in section 1.3 on PPI and H2RA licensing for use in children. Recommendation 1.3.7 has been amended to clarify when metoclopramide, domperidone or erythromycin can be offered.

Minor changes since publication

May 2021: In recommendation 1.3.7 we highlighted the MHRA drug safety updates about the risk of infantile hypertrophic pyloric stenosis with erythromycin, cardiac risks with erythromycin and potential drug interaction of erythromycin with rivaroxaban.

ISBN: 978-1-4731-0931-5

  • National Institute for Health and Care Excellence (NICE)